Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D2.19 - Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?
D2.17 - Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from january 2023 to december 2025
D2.20 - Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing
D2.21 - The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity
D2.29 - Use and knowledge of Phadiatop Infant and Fx5 in children from a primary care healthcare area
D3.70 - Structural and immunological insights into arginine kinases from house dust mites and related arthropods
D3.63 - Molecular Evidence of PR-10 in Cannabis Allergy
D3.64 - Alcohol-Soluble Wheat Proteins as the Likely Allergenic Trigger in a Patient With Reaction to Gin
D3.66 - When dermatitis follows the menstrual cycle: two cases of endogenous progestogen hypersensitivity
D3.67 - Retrospective Evaluation of IgE Panel Utility in Allergy Diagnostics: Insights from Baghdad, Iraq
D3.71 - A research tool for development of in-house specific IgE immunoassays - comparison between different methods
D3.73 - Clinical Performance of Hycor NOVEOS–Based Specific IgE Measurements for the Screening of Respiratory Allergies
D3.74 - Age-related characteristics of children's sensitisation to timothy grass according to component diagnostics
D3.76 - Open-Label Clinical Trial To Evaluate The Effect Of Intranasal Olopatadine/Mometasone And Azelastine/Mometasone On Histamine Reactivity In Skin Prick Tests
D3.77 - Tattoo Ink Allergy? Diagnostic Challenges in Cutaneous Reactions to Tattoo Ink Containing Metals
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download